Treatment Approaches and Sequencing Strategies in Differentiated Thyroid Cancer
EP. 1: Overview on Differentiated Thyroid Cancer (DTC)
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Worden, MD,Marcia Brose, MD, PhD, University of Pennsylvania Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.
EP. 2: Diagnosing DTC: Clinical Workup and Molecular Testing
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Worden, MD,Marcia S. Brose, MD, PhD, University of Pennsylvania Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.
EP. 3: Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.
EP. 4: Practical Considerations for Managing RR DTC With Systemic Therapy
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.
EP. 5: Defining Radioiodine-Refractory Differentiated Thyroid Cancer
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.
EP. 6: RR DTC: Active Surveillance vs Initiating Systemic Therapy
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.
EP. 7: Overview of Available Treatment Options for RR DTC
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.
EP. 8: Quality of Life and Real-World Data in Patients With RR DTC
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.
EP. 9: RR DTC: Managing Adverse Events With Dose Reductions or Holds
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.
EP. 10: Patient Scenario 2: Second-Line Management of RR DTC With Cabozantinib
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.
EP. 11: Clinical Data Behind Second-Line Therapy in RR DTC
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.
EP. 12: Practical Considerations for Utilizing Second-Line Therapy in RR DTC
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.
EP. 13: Patient Scenario 3: Treating RR DTC With an Identified RET Fusion
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.
EP. 14: Optimizing Use of RET Inhibitors in Patients With RR DTC
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.
EP. 15: Sequencing Throughout Multiple Lines of Therapy in RR DTC
ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
